The CEO of Connect Biopharma discusses the unique challenges that patients with asthma and COPD face. Pharmaceutical ...

Among patients with prior severe exacerbations, Nucala reduced the annualised rate of moderate ... exacerbation risk profiles and reinforce the therapeutic relevance of IL-5 inhibition in COPD ...

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a ...

MONDAY, May 12, 2025 (HealthDay News) -- For patients with chronic obstructive pulmonary disease (COPD) with a history ... the time to first moderate or severe exacerbation was longer with ...

For patients with chronic obstructive pulmonary disease (COPD) with a history of ... Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab (419 ...

Mepolizumab significantly reduced the annualized rate of moderate or severe ... among patients with COPD who had been admitted to the hospital with a severe exacerbation and a blood eosinophil ...

As chronic obstructive pulmonary disease (COPD) gets worse ... Like the disease itself, flare-ups may range from mild to severe. Your doctor will help you come up with a plan for how to handle ...

Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of Chronic Obstructive ...

Unscheduled physician office visits, ED visits and unplanned hospitalizations made up the studied COPD-related health care resources. A lower moderate/severe exacerbation event rate was found with ...

In fact, a meta-analysis concluded that exercise is the best available method to strengthen breathing muscles in people with COPD. For people with mild ... COPD is moderate or severe, a ...